After reading the presentation and press release on the phase III clinical trial plans for PI-88 I am starting to wonder if this has been such a great investment for me. So I decided to do a bit of digging and according to the UK cancer research www.info.cancerresearchuk.org the incidence of hepatocellular carcinoma is about 4.5 per 100,000 and accounts for less than 1% of all cancers. So I was wondering if it is reasonable to expect that our company can recruit so many patients (about 800) into the trial in the timeframe outlined? It seems to me that there is a huge potential for timeline and cost blowouts and a fairly small market to be captured when/if they (we) get there. Anyone got any insight to offer? 2012 seems like such a long time to wait for a return.
The above is my opinion and is not investment advice.
PGL Price at posting:
0.0¢ Sentiment: Sell Disclosure: Held
